Vivoryon Brings 'Diversity' To Therapeutic Approach In Alzheimer’s
Ulrich Dauer, CEO Vivoryon Therapeutics, the new name for German biotech Probiodrug, talks to In Vivo about introducing more diversity into the Alzheimer’s disease pipeline.
You may also be interested in...
Plus deals involving Y-Biologics/Pierre Fabre, Contera/Abzu, Chugai/Alebund, Catalyst/DyDo, Spergogenix/Abbiska, Nippon Gene/ERS Genomics, Simcere/Vivoryon, Dr. Reddy’s/Journey Medical and Innovent/Synaffix.
Jhaymee Tynan, assistant vice president of integration at Atrium Health and creator and founder of the 100x2030 Initiative, speaks to In Vivo about her journey into health care, putting the patient first, and the importance of encouraging diversity in the industry.
What are the skills future life sciences leaders will need in order to rise to the top of biopharma and medtech companies? A recent BioTrinity industry panel debated the profile of tomorrow’s leaders.